Glioma targeted therapy: insight into future of molecular approaches
Gliomas are the common type of brain tumors originating from glial cells. Epidemiologically,
gliomas occur among all ages, more often seen in adults, which males are more susceptible …
gliomas occur among all ages, more often seen in adults, which males are more susceptible …
Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance
Glioblastoma multiforme (GBM) is a WHO grade IV glioma and the most common malignant,
primary brain tumor with a 5-year survival of 7.2%. Its highly infiltrative nature, genetic …
primary brain tumor with a 5-year survival of 7.2%. Its highly infiltrative nature, genetic …
Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial
T Todo, H Ito, Y Ino, H Ohtsu, Y Ota, J Shibahara… - Nature medicine, 2022 - nature.com
Abstract This investigator-initiated, phase 2, single-arm trial primarily assessed the efficacy
of G47∆, a triple-mutated, third-generation oncolytic herpes simplex virus type 1, in 19 adult …
of G47∆, a triple-mutated, third-generation oncolytic herpes simplex virus type 1, in 19 adult …
Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial
Background Effective treatments are needed to improve outcomes for high-grade glioma
and low-grade glioma. The activity and safety of dabrafenib plus trametinib were evaluated …
and low-grade glioma. The activity and safety of dabrafenib plus trametinib were evaluated …
[HTML][HTML] EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
M Weller, M van den Bent, M Preusser… - Nature reviews Clinical …, 2021 - nature.com
In response to major changes in diagnostic algorithms and the publication of mature results
from various large clinical trials, the European Association of Neuro-Oncology (EANO) …
from various large clinical trials, the European Association of Neuro-Oncology (EANO) …
Management of glioblastoma: State of the art and future directions
Glioblastoma is the most common malignant primary brain tumor. Overall, the prognosis for
patients with this disease is poor, with a median survival of< 2 years. There is a slight …
patients with this disease is poor, with a median survival of< 2 years. There is a slight …
Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial
DA Reardon, AA Brandes, A Omuro… - JAMA …, 2020 - jamanetwork.com
Importance Clinical outcomes for glioblastoma remain poor. Treatment with immune
checkpoint blockade has shown benefits in many cancer types. To our knowledge, data from …
checkpoint blockade has shown benefits in many cancer types. To our knowledge, data from …
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future …
Glioblastomas are the most common form of malignant primary brain tumor and an important
cause of morbidity and mortality. In recent years there have been important advances in …
cause of morbidity and mortality. In recent years there have been important advances in …
[HTML][HTML] Immunotherapy for glioma: current management and future application
Gliomas are intrinsic brain tumors that originate from neuroglial progenitor cells.
Conventional therapies, including surgery, chemotherapy, and radiotherapy, have achieved …
Conventional therapies, including surgery, chemotherapy, and radiotherapy, have achieved …
Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance
It is well established that multifactorial drug resistance hinders successful cancer treatment.
Tumor cell interactions with the tumor microenvironment (TME) are crucial in epithelial …
Tumor cell interactions with the tumor microenvironment (TME) are crucial in epithelial …